{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:12:49Z","timestamp":1793923969694,"version":"4.8.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23\/00924"],"award-info":[{"award-number":["PI23\/00924"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s41030-025-00338-7","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T03:15:49Z","timestamp":1767496549000},"page":"99-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Drug-Induced Pulmonary Toxicity in the Era of Immunotherapy and Biologics: A Narrative Review of Mechanism, Diagnosis, and Management"],"prefix":"10.1007","volume":"12","author":[{"given":"Josmar J. R\u00edos","family":"Poveda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela Herrera","family":"Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J. Zapata","family":"Huizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"Sellares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Hern\u00e1ndez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"issue":"4","key":"338_CR1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02776-2021","volume":"60","author":"P Spagnolo","year":"2022","unstructured":"Spagnolo P, Bonniaud P, Rossi G, Sverzellati N, Cottin V. Drug-induced interstitial lung disease. Eur Respir J. 2022;60(4):2102776. https:\/\/doi.org\/10.1183\/13993003.02776-2021.","journal-title":"Eur Respir J"},{"issue":"1","key":"338_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1465-9921-13-39","volume":"13","author":"O Matsuno","year":"2012","unstructured":"Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13(1):39. https:\/\/doi.org\/10.1186\/1465-9921-13-39.","journal-title":"Respir Res"},{"issue":"11","key":"338_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00392-010-0181-3","volume":"10","author":"M Schwaiblmair","year":"2010","unstructured":"Schwaiblmair M, Berghaus T, Haeckel T, Wagner T, von Scheidt W. Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect? Clin Res Cardiol. 2010;10(11):693\u2013700. https:\/\/doi.org\/10.1007\/s00392-010-0181-3.","journal-title":"Clin Res Cardiol"},{"issue":"12","key":"338_CR4","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/j.amjcard.2019.09.008","volume":"124","author":"M Ruzieh","year":"2019","unstructured":"Ruzieh M, Moroi MK, Aboujamous NM, Ghahramani M, Naccarelli GV, Mandrola J, et\u00a0al. Meta-analysis comparing the relative risk of adverse events for amiodarone versus placebo. Am J Cardiol. 2019;124(12):1889\u201393. https:\/\/doi.org\/10.1016\/j.amjcard.2019.09.008.","journal-title":"Am J Cardiol"},{"issue":"4","key":"338_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"26","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;26(4):254\u201367. https:\/\/doi.org\/10.1038\/s41571-022-00600-w.","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"338_CR6","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","volume":"78","author":"A Goldman","year":"2021","unstructured":"Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, et\u00a0al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J Am Coll Cardiol. 2021;78(18):1800\u201313. https:\/\/doi.org\/10.1016\/j.jacc.2021.08.044.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"338_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","volume":"41","author":"R Perez-Alvarez","year":"2011","unstructured":"Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, et\u00a0al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41(2):256\u201364. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.11.002.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"338_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1155\/2009\/282540","volume":"16","author":"N Wolkove","year":"2009","unstructured":"Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009;16(2):43\u20138. https:\/\/doi.org\/10.1155\/2009\/282540.","journal-title":"Can Respir J"},{"issue":"7","key":"338_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2165\/11532320-000000000-00000","volume":"33","author":"SA Papiris","year":"2010","unstructured":"Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, Manali ED. Amiodarone. Drug Saf. 2010;33(7):539\u201358. https:\/\/doi.org\/10.2165\/11532320-000000000-00000.","journal-title":"Drug Saf"},{"key":"338_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.693016","author":"JW Fischer","year":"2021","unstructured":"Fischer JW, Bhattarai N. CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.693016.","journal-title":"Front Immunol"},{"issue":"5","key":"338_CR11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/MCP.0b013e3283483ea5","volume":"17","author":"ST Panopoulos","year":"2011","unstructured":"Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med. 2011;17(5):362\u20137. https:\/\/doi.org\/10.1097\/MCP.0b013e3283483ea5.","journal-title":"Curr Opin Pulm Med"},{"issue":"10","key":"338_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jcm7100356","volume":"7","author":"S Skeoch","year":"2018","unstructured":"Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, et\u00a0al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018;7(10):356. https:\/\/doi.org\/10.3390\/jcm7100356.","journal-title":"J Clin Med"},{"issue":"5","key":"338_CR13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.amjmed.2015.08.039","volume":"129","author":"AE Epstein","year":"2016","unstructured":"Epstein AE, Olshansky B, Naccarelli GV, Kennedy JI, Murphy EJ, Goldschlager N. Practical management guide for clinicians who treat patients with amiodarone. Am J Med. 2016;129(5):468\u201375. https:\/\/doi.org\/10.1016\/j.amjmed.2015.08.039.","journal-title":"Am J Med"},{"issue":"1","key":"338_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/1759-7714.13240","volume":"11","author":"H Wang","year":"2020","unstructured":"Wang H, Guo X, Zhou J, Li Y, Duan L, Si X, et\u00a0al. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. Thorac Cancer. 2020;11(1):191\u20137. https:\/\/doi.org\/10.1111\/1759-7714.13240.","journal-title":"Thorac Cancer"},{"issue":"6","key":"338_CR15","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","volume":"154","author":"K Suresh","year":"2018","unstructured":"Suresh K, Naidoo J, Lin CT, Danoff S. Immune checkpoint immunotherapy for non-small cell lung cancer. Chest. 2018;154(6):1416\u201323. https:\/\/doi.org\/10.1016\/j.chest.2018.08.1048.","journal-title":"Chest"},{"issue":"1","key":"338_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et\u00a0al. Chimeric antigen receptor T-cell therapy, assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148.","journal-title":"Nat Rev Clin Oncol"},{"key":"338_CR17","unstructured":"Pneumotox. Drug-induced pulmonary toxicity database. Pneumotox [Internet]. Drug-induced pulmonary toxicity database. 2023 [cited 2025 May 20]. Available from: https:\/\/www.pneumotox.com\/drug\/index\/."},{"key":"338_CR18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00158-2025","author":"CJ Ryerson","year":"2025","unstructured":"Ryerson CJ, Adegunsoye A, Piciucchi S, et\u00a0al. Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS\/ATS statement. Eur Respir J. 2025. https:\/\/doi.org\/10.1183\/13993003.00158-2025.","journal-title":"Eur Respir J"},{"key":"338_CR19","unstructured":"National Cancer Institute (NCI)\/Cancer Therapy Evaluation Program. Common terminology criteria for adverse events (CTCAE) [Internet]. National Cancer Institute. [cited 2025 May 17]. Available from: https:\/\/safetyprofiler-ctep.nci.nih.gov\/safety-profiler\/login.html."},{"issue":"1","key":"338_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et\u00a0al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20(1):44. https:\/\/doi.org\/10.1186\/s12964-022-00854-y.","journal-title":"Cell Commun Signal"},{"issue":"4","key":"338_CR21","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ccell.2025.02.026","volume":"43","author":"H Li","year":"2025","unstructured":"Li H, Zandberg DP, Kulkarni A, Chiosea SI, Santos PM, Isett BR, et\u00a0al. Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies. Cancer Cell. 2025;43(4):757-775.e8. https:\/\/doi.org\/10.1016\/j.ccell.2025.02.026.","journal-title":"Cancer Cell"},{"issue":"10304","key":"338_CR22","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(21)01206-X.","journal-title":"Lancet"},{"issue":"21","key":"338_CR23","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, et\u00a0al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1810865.","journal-title":"N Engl J Med"},{"issue":"14","key":"338_CR24","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S, Rodr\u00edguez-Abreu D, Speranza G, Esteban E, Felip E, D\u00f3mine M, et\u00a0al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non\u2013small-cell lung cancer. J Clin Oncol. 2020;38(14):1505\u201317. https:\/\/doi.org\/10.1200\/JCO.19.03136.","journal-title":"J Clin Oncol"},{"key":"338_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fimmu.2022.948597","volume":"13","author":"T Shao","year":"2022","unstructured":"Shao T, Zhao M, Liang L, Tang W. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer. Front Immunol. 2022;13:26. https:\/\/doi.org\/10.3389\/fimmu.2022.948597.","journal-title":"Front Immunol"},{"issue":"21","key":"338_CR26","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et\u00a0al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%. J Clin Oncol. 2021;39(21):2339\u201349. https:\/\/doi.org\/10.1200\/JCO.21.00174.","journal-title":"J Clin Oncol"},{"key":"338_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170503","author":"MI Ghanbar","year":"2024","unstructured":"Ghanbar MI, Suresh K. Pulmonary toxicity of immune checkpoint immunotherapy. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI170503.","journal-title":"J Clin Invest"},{"issue":"4","key":"338_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","volume":"5","author":"G De Velasco","year":"2017","unstructured":"De Velasco G, Je Y, Boss\u00e9 D, Awad MM, Ott PA, Moreira RB, et\u00a0al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5(4):312\u20138. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0237.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"338_CR29","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1016\/j.cllc.2019.02.018","volume":"20","author":"KR Voong","year":"2019","unstructured":"Voong KR, Hazell SZ, Fu W, Hu C, Lin CT, Ding K, et\u00a0al. Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2019;20(4):e470\u20139. https:\/\/doi.org\/10.1016\/j.cllc.2019.02.018.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"338_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01749-x","volume":"39","author":"X-H Jia","year":"2020","unstructured":"Jia X-H, Geng L-Y, Jiang P-P, Xu H, Nan K-J, Yao Y, et\u00a0al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. J Exp Clin Cancer Res. 2020;39(1):284. https:\/\/doi.org\/10.1186\/s13046-020-01749-x.","journal-title":"J Exp Clin Cancer Res"},{"key":"338_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.698832","author":"X Lin","year":"2021","unstructured":"Lin X, Deng H, Yang Y, Wu J, Qiu G, Li S, et\u00a0al. Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.698832.","journal-title":"Front Oncol"},{"issue":"44","key":"338_CR32","doi-asserted-by":"publisher","first-page":"22246","DOI":"10.1073\/pnas.1908079116","volume":"116","author":"SA Tahir","year":"2019","unstructured":"Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, et\u00a0al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci USA. 2019;116(44):22246\u201351. https:\/\/doi.org\/10.1073\/pnas.1908079116.","journal-title":"Proc Natl Acad Sci USA"},{"key":"338_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.827199","author":"Y Li","year":"2022","unstructured":"Li Y, Jia X, Du Y, Mao Z, Zhang Y, Shen Y, et\u00a0al. Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.827199.","journal-title":"Front Oncol"},{"issue":"2","key":"338_CR34","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s12016-015-8526-3","volume":"50","author":"SS Eng","year":"2016","unstructured":"Eng SS, DeFelice ML. The role and immunobiology of eosinophils in the respiratory system: a comprehensive review. Clin Rev Allergy Immunol. 2016;50(2):140\u201358. https:\/\/doi.org\/10.1007\/s12016-015-8526-3.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"338_CR35","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/1078155217745144","volume":"25","author":"CR Stroud","year":"2019","unstructured":"Stroud CR, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, et\u00a0al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019;25(3):551\u20137. https:\/\/doi.org\/10.1177\/1078155217745144.","journal-title":"J Oncol Pharm Pract"},{"issue":"16","key":"338_CR36","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et\u00a0al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"issue":"4","key":"338_CR37","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388\u201398. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0548.","journal-title":"Cancer Discov"},{"key":"338_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-017-01536-3","author":"H Ledford","year":"2017","unstructured":"Ledford H. Engineered cell therapy for cancer gets thumbs up from FDA advisers. Nature. 2017. https:\/\/doi.org\/10.1038\/d41586-017-01536-3.","journal-title":"Nature"},{"issue":"14","key":"338_CR39","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et\u00a0al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1914347.","journal-title":"N Engl J Med"},{"issue":"1","key":"338_CR40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et\u00a0al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91\u2013103. https:\/\/doi.org\/10.1016\/S1470-2045(21)00591-X.","journal-title":"Lancet Oncol"},{"issue":"10297","key":"338_CR41","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et\u00a0al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8.","journal-title":"Lancet"},{"issue":"25","key":"338_CR42","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et\u00a0al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(25):705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"issue":"30","key":"338_CR43","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(30):3321\u201330. https:\/\/doi.org\/10.1182\/blood-2016-04-703751.","journal-title":"Blood"},{"issue":"5","key":"338_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(5):64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169.","journal-title":"N Engl J Med"},{"key":"338_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fimmu.2022.778192","volume":"27","author":"Z Sun","year":"2022","unstructured":"Sun Z, Xie C, Liu H, Yuan X. CD19 CAR-T cell therapy induced immunotherapy associated interstitial pneumonitis: a case report. Front Immunol. 2022;27:13. https:\/\/doi.org\/10.3389\/fimmu.2022.778192.","journal-title":"Front Immunol"},{"key":"338_CR46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017579","author":"C Gutierrez","year":"2023","unstructured":"Gutierrez C, Neilan T, Grover NS. How I approach optimization of patients at risk of cardiac and pulmonary complication after CAR-T cell therapy. Blood. 2023. https:\/\/doi.org\/10.1182\/blood.2022017579.","journal-title":"Blood"},{"key":"338_CR47","doi-asserted-by":"publisher","unstructured":"Bondeelle L, Di Blasi R, Samy L, Aguinaga L, Lorillon G, Bernard S, et\u00a0al. CAR T cells-associated delayed lung toxicity\u2014A case series. In: ILD\/DPLD of known origin. European Respiratory Society; 2020. p. 746. https:\/\/doi.org\/10.1183\/13993003.congress-2020.746.","DOI":"10.1183\/13993003.congress-2020.746"},{"issue":"35","key":"338_CR48","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et\u00a0al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978\u201392. https:\/\/doi.org\/10.1200\/JCO.21.01992.","journal-title":"J Clin Oncol"},{"key":"338_CR49","doi-asserted-by":"publisher","unstructured":"Wudhikarn K, Soh SY, Huang He, Perales M-A. Toxicity of chimeric antigen receptor T cells and its management. Blood Cell Therapy Off J APBMT. 2021;4(Special Edition). https:\/\/doi.org\/10.31547\/bct-2021-011.","DOI":"10.31547\/bct-2021-011"},{"issue":"1","key":"338_CR50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, et\u00a0al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. https:\/\/doi.org\/10.1186\/s40425-018-0343-9.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"338_CR51","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et\u00a0al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(10):188\u201395. https:\/\/doi.org\/10.1182\/blood-2014-05-552729.","journal-title":"Blood"},{"issue":"4","key":"338_CR52","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1159\/000104866","volume":"76","author":"GA Heresi","year":"2008","unstructured":"Heresi GA, Farver CF, Stoller JK. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab. Respiration. 2008;76(4):449\u201353. https:\/\/doi.org\/10.1159\/000104866.","journal-title":"Respiration"},{"issue":"9","key":"338_CR53","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/rheumatology\/kel220","volume":"45","author":"MT Huggett","year":"2006","unstructured":"Huggett MT, Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology. 2006;45(9):1312\u20133. https:\/\/doi.org\/10.1093\/rheumatology\/kel220.","journal-title":"Rheumatology"},{"issue":"2","key":"338_CR54","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semarthrit.2009.09.001","volume":"40","author":"AA Khasnis","year":"2010","unstructured":"Khasnis AA, Calabrese LH. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum. 2010;40(2):147\u201363. https:\/\/doi.org\/10.1016\/j.semarthrit.2009.09.001.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"338_CR55","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1165\/rcmb.2004-0288OC","volume":"32","author":"DE Sullivan","year":"2005","unstructured":"Sullivan DE, Ferris M, Pociask D, Brody AR. Tumor necrosis factor-\u03b1 induces transforming growth factor-\u03b2 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol. 2005;32(4):342\u20139. https:\/\/doi.org\/10.1165\/rcmb.2004-0288OC.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"338_CR56","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","volume":"43","author":"C Roubille","year":"2014","unstructured":"Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43(5):613\u201326. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.09.005.","journal-title":"Semin Arthritis Rheum"},{"key":"338_CR57","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.2147\/DDDT.S204730","volume":"13","author":"Y Huang","year":"2019","unstructured":"Huang Y, Lin W, Chen Z, Wang Y, Huang Y, Tu S. Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon? Drug Des Dev Ther. 2019;13:2111\u201325. https:\/\/doi.org\/10.2147\/DDDT.S204730.","journal-title":"Drug Des Dev Ther"},{"issue":"8","key":"338_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005615","volume":"4","author":"T Nakashita","year":"2014","unstructured":"Nakashita T, Ando K, Kaneko N, Takahashi K, Motojima S. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open. 2014;4(8):e005615. https:\/\/doi.org\/10.1136\/bmjopen-2014-005615.","journal-title":"BMJ Open"},{"issue":"3","key":"338_CR59","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/14712598.2017.1287169","volume":"17","author":"J Chen","year":"2017","unstructured":"Chen J, Chi S, Li F, Yang J, Cho WC, Liu X. Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies. Expert Opin Biol Ther. 2017;17(3):265\u201383. https:\/\/doi.org\/10.1080\/14712598.2017.1287169.","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"338_CR60","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/bcr-2017-219883","volume":"80","author":"K Bechman","year":"2025","unstructured":"Bechman K, Biddle K, Miracle A, He K, Gibson M, Russell MD, et\u00a0al. Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis. Thorax. 2025;80(7):702\u201310. https:\/\/doi.org\/10.1136\/bcr-2017-219883.","journal-title":"Thorax"},{"issue":"5","key":"338_CR61","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/rheumatology\/kep431","volume":"49","author":"A Massara","year":"2010","unstructured":"Massara A, Cavazzini L, La Corte R, Trotta F. Comment on: Sarcoid-like granulomatosis in patients treated with tumour necrosis factor blockers: 10 cases. Rheumatology. 2010;49(5):1019\u201321. https:\/\/doi.org\/10.1093\/rheumatology\/kep431.","journal-title":"Rheumatology"},{"issue":"1","key":"338_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01948-6","volume":"21","author":"S Kashima","year":"2021","unstructured":"Kashima S, Moriichi K, Ando K, Ueno N, Tanabe H, Yuzawa S, et\u00a0al. Development of pulmonary sarcoidosis in Crohn\u2019s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review. BMC Gastroenterol. 2021;21(1):373. https:\/\/doi.org\/10.1186\/s12876-021-01948-6.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"338_CR63","doi-asserted-by":"publisher","DOI":"10.3402\/ecrj.v2.27178","volume":"2","author":"M Naqibullah","year":"2015","unstructured":"Naqibullah M, Shaker SB, Bach KS, Bendstrup E. Rituximab-induced interstitial lung disease: five case reports. Eur Clin Respir J. 2015;2(1):27178. https:\/\/doi.org\/10.3402\/ecrj.v2.27178.","journal-title":"Eur Clin Respir J"},{"issue":"4","key":"338_CR64","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","volume":"51","author":"AV Hadjinicolaou","year":"2012","unstructured":"Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostor AJK. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology. 2012;51(4):653\u201362. https:\/\/doi.org\/10.1093\/rheumatology\/ker290.","journal-title":"Rheumatology"},{"key":"338_CR65","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pupt.2016.02.002","volume":"37","author":"D Franzen","year":"2016","unstructured":"Franzen D, Ciurea A, Bratton DJ, Clarenbach CF, Latshang TD, Russi EW, et\u00a0al. Effect of rituximab on pulmonary function in patients with rheumatoid arthritis. Pulm Pharmacol Ther. 2016;37:24\u20139. https:\/\/doi.org\/10.1016\/j.pupt.2016.02.002.","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"338_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-022-01926-y","volume":"22","author":"WC Kwok","year":"2022","unstructured":"Kwok WC, Ma TF, Chan JWM, Pang HH, Ho JCM. A multicenter retrospective cohort study on predicting the risk for amiodarone pulmonary toxicity. BMC Pulm Med. 2022;22(1):128. https:\/\/doi.org\/10.1186\/s12890-022-01926-y.","journal-title":"BMC Pulm Med"},{"key":"338_CR67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.12659\/AJCR.920386","volume":"17","author":"AJ Chin","year":"2020","unstructured":"Chin AJ, Rashid S, Gharibeh TR, Kibbe PS, Wynbrandt JH. Interstitial lung disease secondary to long-term nitrofurantoin use. Am J Case Rep. 2020;17:21. https:\/\/doi.org\/10.12659\/AJCR.920386.","journal-title":"Am J Case Rep"},{"issue":"1","key":"338_CR68","doi-asserted-by":"publisher","DOI":"10.1007\/s40800-016-0037-5","volume":"3","author":"KA Rambaran","year":"2016","unstructured":"Rambaran KA, Seifert CF. Unrecognized interstitial lung disease as a result of chronic nitrofurantoin use. Drug Saf Case Rep. 2016;3(1):13. https:\/\/doi.org\/10.1007\/s40800-016-0037-5.","journal-title":"Drug Saf Case Rep"},{"issue":"4","key":"338_CR69","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000079633","volume":"71","author":"P Camus","year":"2004","unstructured":"Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004;71(4):301\u201326. https:\/\/doi.org\/10.1159\/000079633.","journal-title":"Respiration"},{"key":"338_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/toxics13050382","author":"AD Kaye","year":"2025","unstructured":"Kaye AD, Shah SS, LaHaye L, Hennagin JA, Ardoin AK, Dubuisson A, et\u00a0al. Nitrofurantoin-induced pulmonary toxicity: mechanisms, diagnosis, and management. Toxics. 2025. https:\/\/doi.org\/10.3390\/toxics13050382.","journal-title":"Toxics"},{"issue":"10","key":"338_CR71","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.4065\/80.10.1298","volume":"80","author":"JL Mendez","year":"2005","unstructured":"Mendez JL, Nadrous HF, Hartman TE, Ryu JH. Chronic nitrofurantoin-induced lung disease. Mayo Clin Proc. 2005;80(10):1298\u2013302. https:\/\/doi.org\/10.4065\/80.10.1298.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"338_CR72","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.chest.2021.06.057","volume":"161","author":"V Tzilas","year":"2022","unstructured":"Tzilas V, Charokopos A, Kolilekas L, Manali E, Papiris S, Ryu JH, et\u00a0al. Presenting features and clinical course of chronic nitrofurantoin-induced lung toxicity. Chest. 2022;161(3):748\u201352. https:\/\/doi.org\/10.1016\/j.chest.2021.06.057.","journal-title":"Chest"},{"issue":"2","key":"338_CR73","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4103\/0022-3859.32211","volume":"53","author":"S Bhullar","year":"2007","unstructured":"Bhullar S, Lele S, Kraman S. Severe nitrofurantoin lung disease resolving without the use of steroids. J Postgrad Med. 2007;53(2):111\u20133. https:\/\/doi.org\/10.4103\/0022-3859.32211.","journal-title":"J Postgrad Med"},{"key":"338_CR74","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v64i5.1072","author":"Z Kanji","year":"2011","unstructured":"Kanji Z, Su VCH, Mainra R. Nitrofurantoin-induced pulmonary reaction involving respiratory symptoms: case report. Can J Hosp Pharm. 2011. https:\/\/doi.org\/10.4212\/cjhp.v64i5.1072.","journal-title":"Can J Hosp Pharm"},{"key":"338_CR75","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.rmcr.2015.01.002","volume":"14","author":"B Lee","year":"2015","unstructured":"Lee B, Balavenkataraman A, Sanghavi D, Walter K. Recurrent nitrofurantoin-induced giant cell interstitial pneumonia: case report and literature review. Respir Med Case Rep. 2015;14:49\u201352. https:\/\/doi.org\/10.1016\/j.rmcr.2015.01.002.","journal-title":"Respir Med Case Rep"},{"issue":"3","key":"338_CR76","doi-asserted-by":"publisher","first-page":"337","DOI":"10.4104\/pcrj.2012.00059","volume":"21","author":"Y Madani","year":"2012","unstructured":"Madani Y, Mann B. Nitrofurantoin-induced lung disease and prophylaxis of urinary tract infections. Prim Care Respir J. 2012;21(3):337\u201341. https:\/\/doi.org\/10.4104\/pcrj.2012.00059.","journal-title":"Prim Care Respir J"},{"issue":"6","key":"338_CR77","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4103\/0971-4065.143302","volume":"24","author":"G Naidu","year":"2014","unstructured":"Naidu G, Deepthi P, Karthik Kr K, Das U, Swarnalatha G, Gangadhar T. Nitrofurantoin induced interstitial lung disease. Indian J Nephrol. 2014;24(6):405. https:\/\/doi.org\/10.4103\/0971-4065.143302.","journal-title":"Indian J Nephrol"},{"key":"338_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-213967","author":"H Syed","year":"2016","unstructured":"Syed H, Bachuwa G, Upadhaya S, Abed F. Nitrofurantoin-induced interstitial pneumonitis: albeit rare, should not be missed. BMJ Case Rep. 2016. https:\/\/doi.org\/10.1136\/bcr-2015-213967.","journal-title":"BMJ Case Rep"},{"issue":"12","key":"338_CR79","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/art.41451","volume":"72","author":"JM Kremer","year":"2020","unstructured":"Kremer JM. Methotrexate pulmonary toxicity: deep inspiration. Arthritis Rheumatol. 2020;72(12):1959\u201362. https:\/\/doi.org\/10.1002\/art.41451.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"338_CR80","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.tox.2008.11.016","volume":"256","author":"Y-J Kim","year":"2009","unstructured":"Kim Y-J, Song M, Ryu J-C. Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology. 2009;256(3):183\u201390. https:\/\/doi.org\/10.1016\/j.tox.2008.11.016.","journal-title":"Toxicology"},{"issue":"4","key":"338_CR81","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40265-014-0190-z","volume":"74","author":"RW Hallowell","year":"2014","unstructured":"Hallowell RW, Horton MR. Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced. Drugs. 2014;74(4):443\u201350. https:\/\/doi.org\/10.1007\/s40265-014-0190-z.","journal-title":"Drugs"},{"issue":"11","key":"338_CR82","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/rheumatology\/kez337","volume":"58","author":"GE Fragoulis","year":"2019","unstructured":"Fragoulis GE, Conway R, Nikiphorou E. Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature. Rheumatology. 2019;58(11):1900\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/kez337.","journal-title":"Rheumatology"},{"issue":"5","key":"338_CR83","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/rheumatology\/35.5.441","volume":"35","author":"P Hiliquin","year":"1996","unstructured":"Hiliquin P, Renoux M, Perrot S, Pu\u00e9chal X, Menk\u00e8s CJ. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Rheumatology. 1996;35(5):441\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/35.5.441.","journal-title":"Rheumatology"},{"issue":"2","key":"338_CR84","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1034\/j.1399-3003.2000.15b25.x","volume":"15","author":"S Imokawa","year":"2000","unstructured":"Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000;15(2):373. https:\/\/doi.org\/10.1034\/j.1399-3003.2000.15b25.x.","journal-title":"Eur Respir J"},{"issue":"4","key":"338_CR85","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/00005382-200310000-00004","volume":"18","author":"H Arakawa","year":"2003","unstructured":"Arakawa H, Yamasaki M, Kurihara Y, Yamada H, Nakajima Y. Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imaging. 2003;18(4):231\u20136. https:\/\/doi.org\/10.1097\/00005382-200310000-00004.","journal-title":"J Thorac Imaging"},{"issue":"10","key":"338_CR86","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s10067-011-1765-7","volume":"30","author":"F Rondon","year":"2011","unstructured":"Rondon F, Mendez O, Spinel N, Ochoa C, Saavedra C, Penaranda E, et\u00a0al. Methotrexate-induced pulmonary toxicity in psoriatic arthritis (PsA): case presentation and literature review. Clin Rheumatol. 2011;30(10):1379\u201384. https:\/\/doi.org\/10.1007\/s10067-011-1765-7.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"338_CR87","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1053\/j.jvca.2015.06.019","volume":"31","author":"AD Oprea","year":"2017","unstructured":"Oprea AD. Chemotherapy agents with known pulmonary side effects and their anesthetic and critical care implications. J Cardiothorac Vasc Anesth. 2017;31(6):2227\u201335. https:\/\/doi.org\/10.1053\/j.jvca.2015.06.019.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"338_CR88","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1183\/2312508X.10020421","volume-title":"Lung diseases and cancer","author":"T Karampitsakos","year":"2022","unstructured":"Karampitsakos T, Sampsonas F, Spagnolo P, et\u00a0al. Pulmonary effects of cancer treatments. In: Mart\u00ednez-Garc\u00eda M\u00c1, Gaga M, Fong KM, editors., et\u00a0al., Lung diseases and cancer. Sheffield: European Respiratory Society; 2022. p. 253\u201364. https:\/\/doi.org\/10.1183\/2312508X.10020421."},{"issue":"3","key":"338_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713","volume":"15","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel). 2023;15(3):713. https:\/\/doi.org\/10.3390\/cancers15030713.","journal-title":"Cancers (Basel)"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00338-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-025-00338-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00338-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:31:14Z","timestamp":1773667874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-025-00338-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["338"],"URL":"https:\/\/doi.org\/10.1007\/s41030-025-00338-7","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]},"assertion":[{"value":"18 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fernanda Hern\u00e1ndez-Gonz\u00e1lez and Jacobo Sellares report honoraria for lectures, educational events, and support for attending meetings from Roche, Boehringer-Ingelheim, Aztra Zeneca, Gebro, and GSK outside the submitted work. J.S. discloses consulting fees from Boehringer-Ingelheim and Alofarma, and grants from Roche and Boehringer-Ingelheim, all outside the submitted work. Jacobo Sellares is an editorial board member of Pulmonary Therapy. Jacobo Sellares was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. The remaining authors, Josmar Jesvi R\u00edos Poveda, Manuela Herrera Tamayo, and Juan Jos\u00e9 Zapata Huizi, have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This narrative review is based on previously published studies and does not include any new studies with human participants or animals performed by the authors. The manuscript includes deidentified radiological images from the authors\u2019 clinical practice. In accordance with the policies of the Hospital Cl\u00ednic de Barcelona, this activity does not constitute human subjects research and institutional review board\/ethics committee approval was not required. Written informed consent for publication of the images was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}